The Following is a List of the Patents assigned to The Catholic University of America:
* Inventors from The Catholic University of America are in bold letters.
Patent Number | Title |
---|---|
10,411,940 | Polymers grafted with organic phosphorous compounds for extracting uranium from solutions |
10,407,470 | Method of inducing an immune response against human immunodeficiency virus comprising administering immunogenic compositions comprising authentic trimeric HIV-1 envelope glycoproteins containing a long linker and tag |
10,127,568 | Systems and methods for improving the accuracy of day-ahead load forecasts on an electric utility grid |
10,005,819 | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag |
9,975,924 | Approach to produce HIV-1 GP140 envelope protein trimers |
9,944,679 | Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag |
9,919,974 | High-strength geopolymer composite cellular concrete |
9,850,288 | Method of purifying authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag |
9,834,583 | Authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag |
9,834,479 | Tailored geopolymer composite binders for cement and concrete applications |
9,827,457 | Compositions and methods for converting hazardous waste glass into non-hazardous products |
9,701,722 | Designing a soluble full-length HIV-1 gp41 trimer |
9,580,477 | Approach to produce HIV-1 GP140 envelope protein trimers |
9,523,101 | Protein and nucleic acid delivery vehicles, components and mechanisms thereof |
9,365,867 | Protein and nucleic acid delivery vehicles, components and mechanisms thereof |
9,328,149 | Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines |
9,328,145 | Designing a soluble full-length HIV-1 gp41 trimer |
9,187,765 | In vitro and In vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine |
9,163,262 | In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine |
9,090,508 | Geopolymer composite for ultra high performance concrete |
8,802,418 | Protein and nucleic acid delivery vehicles, components and mechanisms thereof |
8,685,694 | Methods and compositions comprising bacteriophage nanoparticles |
8,308,299 | Lenslet array for retinal oximetry |
8,257,410 | Use of weak stressors to enhance the effectiveness of ionizing radiation and other treatments of disease |
8,148,130 | T4 bacteriophage bound to a substrate |
8,014,846 | Methods of using magnetic fields to uniformly induce electric fields for therapeutic purposes |
7,997,732 | Lenslet array for retinal oximetry |
7,879,076 | Use of weak stressors to enhance the effectiveness of ionizing radiation and other treatments of disease |
RE40,938 | Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof |
RE40,931 | Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof |
RE40,912 | Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof |
7,587,230 | Method of using magnetic fields to uniformly induce electric fields for therapeutic purposes |
7,367,988 | Use of electromagnetic fields in cancer and other therapies |
6,856,839 | Use of electromagnetic fields in cancer and other therapies |
6,853,864 | Use of electromagnetic fields in cancer and other therapies |
6,728,396 | Independent component imaging |
6,511,442 | System for evaluating and promoting development in persons with severe disabilities |
6,263,878 | Means for protecting living systems from adverse effects of electric, magnetic and electromagnetic fields |
6,159,953 | Anti-malarial composition and method of use |
5,968,527 | Protection of living systems from the adverse effects of stress |
5,566,685 | Protection of living systems from adverse effects of electric, magnetic and electromagnetic fields |
5,562,721 | Method of using endocardial impedance for assessing tissue heating during ablation |
5,544,665 | Protection of living systems from adverse effects of electric, magnetic and electromagnetic fields |
5,450,859 | Protection of living systems from adverse effects of electric, magnetic and electromagnetic fields |
5,447,529 | Method of using endocardial impedance for determining electrode-tissue contact, appropriate sites for arrhythmia ablation and tissue heating during ablation |
5,434,331 | Removal of radioactive or heavy metal contaminants by means of non-persistent complexing agents |
5,386,063 | Synthesis of (all-E)-2,7,-dimethylocta-2,4,6-triene-1,8-dial.sup.13 C.sub.4 |
5,382,714 | Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof |
5,314,815 | Method for temporarily inhibiting or deactivating serine hydrolase and adduct of serine hydrolase with a phosphonate or phosphate compound |
5,306,700 | Dense melt-based ceramic superconductors |
5,281,523 | Temporary inactivation of serine hydrolases using nitrophenyl phenacyl phosphonates |
5,270,292 | Method for the formation of high temperature semiconductors |
-
Patent Licensing Information
Learn More -
US Patent Information
Learn More -
Foreign Patent Information
Learn More -
CUA Patent Policy
Learn More